MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).

A live webcast of Mesoblast’s presentation can be accessed via either http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19955 or  http://investorsmedia.mesoblast.com

The archived webcast will be available in the Events and Presentations section of the Company's website via www.mesoblast.com.

About Mesoblast
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in cell-based medicines.  The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.

For further information, please contact:

Julie Meldrum
Global Head of Corporate Communications
Mesoblast Limited
T: +61 3 9639 6036  
E: julie.meldrum@mesoblast.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.